Nimesulide 100 mg Ban To Prevent Health Risks
- Union Health Ministry restricts higher-dose painkiller formulations
- ICMR findings trigger action over liver, kidney, and environmental harm
The Union Health Ministry has banned the manufacture and sale of Nimesulide oral formulations above 100 mg to safeguard public health and prevent environmental damage. The decision is effective immediately and applies to immediate release versions of the painkiller. Officials said the move aims to reduce serious health risks linked to higher doses of the drug.
The ban follows a critical report by the Indian Council of Medical Research. Scientists found that while Nimesulide helps reduce fever, higher doses often cause severe liver damage. The report also warned of kidney-related risks. According to experts cited in the findings, these dangers increase among elderly patients and people with existing health conditions. Therefore, the ministry decided to limit the dosage strictly to 100 mg.
ICMR report flags liver and kidney risks
Health officials have also reclassified Nimesulide as a second line option. This means doctors should prescribe it only when safer medicines such as Paracetamol fail. The reclassification reflects growing concern within the medical community about hepatotoxicity linked to higher doses. Officials stressed that the new rule does not question the drug’s ability to reduce fever, but rather addresses the dangers of misuse and overuse.
Meanwhile, the ministry highlighted that the ban is not limited to human health concerns. Veterinary use of Nimesulide has been found to be lethal for vultures. When vultures feed on cattle treated with the drug, they suffer rapid kidney failure and die within 24 hours. This has contributed to a serious decline in vulture populations across India. Therefore, by limiting human dosages and banning animal use, the government aims to close loopholes that allowed large animal vials to be diverted for human consumption.
Drug availability limited to 100 mg strength
Following the order, common brands such as Nise, Nicip, and Nimulid will now be sold only in 100 mg strength. Drug regulatory authorities have advised the public to check their medicine cabinets carefully. They also cautioned people against using Nimesulide for children, pregnant women, or as a first choice for minor aches and pain.
Later, officials reiterated that the decision reflects a balance between medical use and safety. The ministry said strict enforcement will ensure compliance and reduce preventable harm linked to higher-dose formulations.
Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe. Click to follow Indtoday’s Facebook page, Twitter, and Instagram. For all the latest Hyderabad News updates
